Last updated: July 25, 2026
Litigation summary and analysis for Alza Corporation v. Kremers Urban LLC (1:10-cv-00023): What patents were at issue, what claims were made, and how did the case end?
What was the dispute in Alza Corporation v. Kremers Urban LLC, 1:10-cv-00023?
Case caption: Alza Corporation v. Kremers Urban LLC
Docket: 1:10-cv-00023
Court/jurisdiction: Not stated in the provided record, and no litigation documents are provided here.
Result: Insufficient information to produce a complete and accurate litigation summary (claims asserted, patents-in-suit, procedural posture, claim construction outcomes, motions, final judgment, and any settlement or licensing terms).
What patents were asserted in Alza v. Kremers Urban (1:10-cv-00023)?
No patents-in-suit, asserted claims, or Orange Book listings are provided in the input.
Which ALZA patents typically appear in Kremers Urban challenges, and what would be relevant here?
ALZA’s most common patent themes in FDA-related disputes include:
- controlled-release and drug delivery technologies
- formulations and membrane-controlled systems
- method-of-manufacturing claims for extended-release performance
No specific patents are provided for this docket, so a correct mapping cannot be produced.
Who were the parties, and what roles did they play in the litigation?
No party roles are provided beyond the caption.
What is the likely procedural posture implied by the case number?
A docket number alone does not establish:
- whether the case was a Hatch-Waxman patent infringement case
- whether it was a declaratory judgment
- whether it followed an ANDA, 505(b)(2), or 510(k) regulatory filing
Without filings or docket entries, an accurate posture cannot be stated.
How did the court rule in Alza v. Kremers Urban (1:10-cv-00023)?
No orders, claim construction rulings, summary judgment outcomes, trial outcomes, or final judgment dates are provided.
What claim-construction and infringement outcomes matter most?
For IP-to-regulatory cases, the business-relevant milestones are typically:
- patents construed (terms, scope, priority)
- infringement findings by asserted element
- validity challenges (novelty, obviousness, written description/enablement, indefiniteness, inequitable conduct)
- injunction status and any carve-outs
None of these details are available in the provided content.
Did the parties reach a settlement, and what were the commercial terms?
No settlement agreement, covenant-not-to-sue, agreed design-around, launch dates, or license terms are provided.
How does this docket affect generic or biosimilar launch risk?
No regulatory timeline, ANDA/BLA status, or exclusivity window data is provided.
What would determine launch risk in a typical ALZA-controlled release patent case?
- whether the asserted patents are method-of-use vs formulation vs manufacturing
- whether infringement theories map to the generic’s ANDA description and label
- whether the generic design-around changes release rate, mechanism, or materials
- whether any court stayed enforcement pending appeal
No docket-specific facts are provided.
Which Orange Book patents were implicated, and what was the FDA status?
No drug name, reference product, NDA/BLA number, or Orange Book patent list is provided.
What is the Orange Book status of the relevant patents?
Not stated in the input; cannot be determined from the provided information.
Litigation timeline analysis: key events, dates, and their implications
No docket events are provided. A timeline cannot be accurately constructed.
Strength of the patent estate and litigation strategy: what the outcome would mean for future challenges
No asserted patents or rulings are provided. A validity and enforceability analysis cannot be tied to this specific case.
Key Takeaways
No litigation summary, no patent mapping, and no outcome analysis can be produced from the provided input alone.
FAQs
- What does docket “1:10-cv-00023” indicate about the likely regulatory trigger (ANDA/BLA vs declaratory judgment)?
- Which patents-in-suit are most commonly asserted by ALZA in controlled-release formulation disputes, and how do they differ by technology class?
- What court rulings most strongly predict whether a generic controlled-release product can launch during appeal?
- How do settlement terms in Hatch-Waxman cases typically allocate launch dates and design-around obligations?
- What evidence does the court rely on to compare drug-release performance between branded and generic products in controlled-release patent cases?
References
None.
